Table 1.
Baseline demographic, clinical, and laboratory characteristics at initial presentation (n = 18).
| Characteristic | Value |
|---|---|
| Age, median years (IQR) | 4.0 (2.3–8.5) |
| Age range, months (years) | 4–144 (0.3–12.0) |
| Age, mean years (SD) | 5.1 (3.9) |
| Sex, female/male, n (%) | 11 (61.1) / 7 (38.9) |
| Weight, mean kg (SD) | 18.4 (11.4) |
| Weight range, kg | 5.9–46.1 |
| Clinical population: AKI / stage 5 CKD, n (%) | 16 (88.9) / 2 (11.1) |
| Intensive care unit admission, n (%) | 14 (77.8) |
| Mechanical ventilation, n (%) | 7 (38.9) |
| Inotrope use, n (%) | 5 (27.8) |
| Fluid overload at presentation, n (%) | 7 (38.9) |
| Documented comorbidity, n (%) | 5 (27.8) |
| KDIGO AKI stage available, n/N (%) | 16/16 (100) |
| KDIGO stage 2 / stage 3 among staged AKI, n/N (%) | 1/16 (6.3) / 15/16 (93.8) |
| Metabolic acidosis, n (%) | 9 (50.0) |
| Serum urea, mmol/L, median (IQR) | 28.5 (18.3–45.5) |
| Serum creatinine, µmol/L, median (IQR) | 509 (184–742) |
| Serum potassium, mmol/L, median (IQR) | 4.7 (4.0–5.6) |
| Serum sodium, mmol/L, median (IQR) | 133 (129–136) |
| Hemoglobin, g/dL, median (IQR) | 8.0 (7.0–10.0) |
| Platelet count, ×10⁹/L, median (IQR) | 138 (76–249) |
| Blood pH among children with acidosis, median (IQR) | 7.24 (7.20–7.34) |
| Bicarbonate among children with acidosis, mmol/L, median (IQR) | 12.6 (11.2–15.7) |
| Urgent KRT indication: severe hypertension/hypertensive emergency, n (%) | 9 (50.0) |
| Urgent KRT indication: fluid overload/pulmonary edema/anuria, n (%) | 7 (38.9) |
| Urgent KRT indication: hyperkalemia, n (%) | 2 (11.1) |
| Urgent KRT indication: uremic symptoms/encephalopathy, n (%) | 2 (11.1) |
| Urgent KRT indication: persistent metabolic acidosis, n (%) | 1 (5.6) |
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; IQR, interquartile range; KDIGO, Kidney Disease Improving Global Outcomes; KRT, kidney replacement therapy; SD, standard deviation.